A Multi-center Phase II Study evaluating efficacy and safety of Dasatinib in Patients with newly diagnosed Philadelphia(Ph) chromosome positive Chronic Myeloid Leukemia in chronic phase.

A Multi-center Phase II Study evaluating efficacy and safety of Dasatinib in Patients with newly diagnosed Philadelphia(Ph) chromosome positive Chronic Myeloid Leukemia in chronic phase. - A Multi-center Phase II Study evaluating efficacy and safety of Dasatinib.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005843

Enrollment

Registered

2011-06-24

Start date

2011-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Myeloid Leukemia

Interventions

Dasatinib will be administered at 100 mg after breakfast once daily for 24 months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic Myeloid Leukemia in chronic phase

Exclusion criteria

Exclusion criteria: Previous treatment with TKI or IFN-alpha

Design outcomes

Primary

Measure	Time frame
A major molecular response(MMR) rate by 12 months after the initiation of Dasatinib treatment	—

Countries

Japan

Contacts

Public ContactTomoiku Takaku

Juntendo University School of Medicine Department of Hematology

ttakaku@juntendo.ac.jp0338133111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026